Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2019 | 1 |
2020 | 1 |
2023 | 2 |
2024 | 0 |
Search Results
4 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study.
Hepatology. 2023 Aug 1;78(2):397-415. doi: 10.1097/HEP.0000000000000395. Epub 2023 Apr 6.
Hepatology. 2023.
PMID: 37386786
Free PMC article.
Clinical Trial.
A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease.
Romero-Gómez M, Lawitz E, Shankar RR, Chaudhri E, Liu J, Lam RLH, Kaufman KD, Engel SS; MK-6024 P001 Study Group.
Romero-Gómez M, et al.
J Hepatol. 2023 Oct;79(4):888-897. doi: 10.1016/j.jhep.2023.05.013. Epub 2023 Jun 22.
J Hepatol. 2023.
PMID: 37355043
Free article.
Clinical Trial.
Item in Clipboard
Estimation of visceral fat is useful for the diagnosis of significant fibrosis in patients with non-alcoholic fatty liver disease.
Hernández-Conde M, Llop E, Carrillo CF, Tormo B, Abad J, Rodriguez L, Perelló C, Gomez ML, Martínez-Porras JL, Puga NF, Trapero-Marugan M, Fraga E, Aracil CF, Panero JLC.
Hernández-Conde M, et al. Among authors: panero jlc.
World J Gastroenterol. 2020 Nov 14;26(42):6658-6668. doi: 10.3748/wjg.v26.i42.6658.
World J Gastroenterol. 2020.
PMID: 33268953
Free PMC article.
Item in Clipboard
Efficacy and safety of a two-drug direct-acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6.
Lawitz E, Gane E, Feld JJ, Buti M, Foster GR, Rabinovitz M, Burnevich E, Katchman H, Tomasiewicz K, Lahser F, Jackson B, Shaughnessy M, Klopfer S, Yeh WW, Robertson MN, Hanna GJ, Barr E, Platt HL; C-BREEZE-2 Study Investigators.
Lawitz E, et al.
J Viral Hepat. 2019 Sep;26(9):1127-1138. doi: 10.1111/jvh.13132. Epub 2019 Jul 11.
J Viral Hepat. 2019.
PMID: 31108015
Clinical Trial.
Item in Clipboard
Cite
Cite